IL21 and esophageal squamous cell carcinoma: In conclusion, IL-21 could efficiently restore impaired ADCC in patients with ESCC, suggesting that the combination therapy of Trastuzumab or Cetuximab with IL-21 might lead to an enhancement of the anti-tumour effect.